Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1179P - The effect of neoadjuvant chemotherapy / chemoradiotherapy on tumor tissue PD-L1 and VISTA expression levels in non-small cell lung cancers (NSCLC)

Date

16 Sep 2021

Session

ePoster Display

Topics

Immunotherapy;  Pathology/Molecular Biology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Orhun Akdogan

Citation

Annals of Oncology (2021) 32 (suppl_5): S939-S948. 10.1016/annonc/annonc728

Authors

O. Akdogan1, O. Sutcuoglu2, B. Öğüt3, N. Akyurek4, N. Özdemir5, A. Özet5, O. Yazıcı5

Author affiliations

  • 1 Internal Medicine, Gazi University Faculty of Medicine, 06200 - Ankara/TR
  • 2 Medical Oncology, Gazi University - Faculty of Medicine, 06200 - Ankara/TR
  • 3 Pathology, Gazi University - Faculty of Medicine, 06200 - Ankara/TR
  • 4 Pathology, Gazi University Faculty of Medicine, 06800 - Ankara/TR
  • 5 Medical Oncology, Gazi University Faculty of Medicine, 06500 - Ankara/TR
More

Abstract 1179P

Background

PD-L1 and VISTA (V-domain Ig suppressor of T-Cell Activation) are important checkpoint control points and plays an immunomodulatory role in patients with NSCLC. In addition, radiation has been shown to induce tumor antigen release and increase PD-L1 expression. Therefore, in this study, we aimed to evaluate the expression level of PD-L1 and VISTA after neoadjuvant chemotherapy or chemoradiotherapy in Stage III NSCLC patients.

Methods

The Stage III NSCLC patients who received neoadjuvant chemotherapy or chemoradiotherapy and operated after that therapies were included in the study. The expression levels of PD-L1 and VISTA between pre-and post- treatment tumor tissue was compared.

Results

Thirty four patients were included in the study. PD-L1 level of 64.7% (n=22) patients at the time of diagnosis was <1%, after neoadjuvant chemotherapy / chemoradiotherapy the PD-L1 level of 32.3% (n=11) patients was evaluated as <1%, and an increase in the PD-L1 level was found in 41.1% (n=14) patients after treatment (p= 0.004). Vista level of 58.8% (n=20) patients at the time of diagnosis was <1%, it was found that the Vista level of 35.2% (n=12) patients after neoadjuvant chemotherapy / chemoradiotherapy was <1% and 44% (n=15) patients had an increase in Vista level after treatment (p = 0.025). There was no relationship between VISTA expression and survival (p: 0.53), but high PD-L1 expression at the time of diagnosis was associated with poor prognosis (p = 0.003). Table: 1179P

PD-L1 and VISTA expression levels of first and second biopsies

First biopsy PD-L1 TPS Second biopsy PD-L1 TPS P-value
0 1 2 3 0 1 2 3
n 22 3 3 6 11 9 3 11 0,004
% 64,7 8,8 8,8 17,6 32,3 26,4 8,8 32,3
First biopsy VISTA IC Second biopsy VISTA IC P-value
0 1 2 3 0 1 2 3
n 20 3 3 8 12 3 5 14 0,025
% 58,8 8,8 8,8 23,5 35,2 8,8 14,7 41,1

Conclusions

Our preliminary results demonstrated that in the stage III NSCLC patients chemotherapy and chemoradiotherapy can be used as immunizers by increasing expression levels of PD-L1 and VISTA.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Turkish Society of Medical Oncology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.